WO2000050058A1 - Cerebrospinal and vascular pharmaceutical composition and process for preparing the same - Google Patents
Cerebrospinal and vascular pharmaceutical composition and process for preparing the same Download PDFInfo
- Publication number
- WO2000050058A1 WO2000050058A1 PCT/US1999/004359 US9904359W WO0050058A1 WO 2000050058 A1 WO2000050058 A1 WO 2000050058A1 US 9904359 W US9904359 W US 9904359W WO 0050058 A1 WO0050058 A1 WO 0050058A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyclosporin
- dmso
- administering
- patient
- brain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- This invention relates to pharmaceutical compositions that facilitate the administration of cyclosporins, particularly into cerebrospinal and vascular fluid spaces.
- Cyclosporin A is an immunosuppressive drug.
- the above mentioned treatment medication has already been described, in United States Pat. No. 4,117,118 and numerous patents since, which relate to its production, formulation and immunosuppressive properties.
- Cyclosporin A is a product of the fungus Tolypocladium Inflatum Gams. It is a cyclic poly-amino acid molecule, consisting of 11 amino acids. One of the amino acids is unique for cyclosporin A, a ⁇ -hydroxy amino acid called butenyl-methyl-threonin (MeBmt). The molecular weight is 1202.6 and the chemical composition is C 62 H ⁇ n N ⁇ O 12 .
- the molecule is highly lipophilic, and therefore virtually insoluble in water.
- the drug is transported in the blood within red blood cells to about 58%, and the remaining approximately 10-20% in leukocytes, and 33% bound to plasma proteins.
- cyclosporin A is bound to high-density lipoprotein, low-density lipoproteins, very-low density lipoproteins and a small fraction to albumin. A very small fraction is free in plasma.
- the drug undergoes extensive metabolism, mainly in the liver by the cytochrome P450 system.
- cytochrome P450 There are at least 30 known metabolites of cyclosporin A, with various chemical modifications, such as hydroxylation, demethylation, oxidation and epoxide formations.
- cyclosporin A differing for example in one amino acid, which have similar pharmacological properties.
- cyclosporin A and its metabolites do not pass the blood-brain barrier.
- the glycoprotein-p transporter is poisoned, or the blood-brain barrier is disrupted, cyclosporin is able to cross it and come into contact with neurons.
- Several analogs of cyclosporin are able to readily cross the blood-brain barrier.
- cyclosporin Several analogs of cyclosporin are not immunosuppressants. There is a subset of analogs of cyclosporin that both readily cross the blood-brain barrier and are not immunosuppressants.
- the family of cyclosporins includes cyclosporin A, cyclosporin C, cyclosporin D, and cyclosporin G.
- Some known metabolites of cyclosporin A include the following : (according to Hawk's Cay nomenclature) AMI, AM9, AMlc, AM4N, AM 19, AMlc9, AMlc4N9, AM1A, AMI A4N, AMI Ac, AM1AL, AMI Id, AM69, AM4N9, AM14N, AM14N9, AM4N69, AM99N, Dihydro-CsA, Dihydro-CsC, Dihydro-CsD, Dihydro- CsG, Ml 7, AMlc-GLC, sulphate conjugate of cyclosporin, BHlla, BH15a, B, G, E, (and with come overlap with the Hawk's above, according to Maurer's nomenclature) Ml, M2, M3, M4, M5, M6, M7, M8, M9, M10, Ml 1, M12, M13, M14, M15, M16, M17, M18, M19,
- metabolites of cyclosporin G include GM1, GM9, GM4N, GMlc, GMlc9, and GM19.
- Modified cyclosporins include modified C-9 amino acid analogs, modified 8- amino acid analogs, modified 6-position analogs containing MeAla or MeAbu residue, and SDZ 209-313, SDZ-205-549, SDZ-033-243, and SDZ-PSC-833.
- cyclosporins including cyclosporin A, all derivatives, variants, amino acid variants, metabolites, including variations of mono-, di- and trihydroxylates, N-demethylates, aldehydes, carboxylates, conjugates, sulphates, glucuronides, intramolecular cyclizations and those without a cyclic structure as well as shorter peptides and amino acids and their derivatives and salts with or without immunosuppressive properties and whether able to cross the blood brain barrier or not will hereinafter be referred to as cyclosporin or cyclosporins.
- Cyclosporins are highly lipophilic and virtually insoluble in water. They require an emulsifier to remain in aqueous phase, such as cremophore or Labrafil.
- emulsifiers are anaphylactic, and are neurotoxic.
- our aim was to create a unique cerebrospinal pharmaceutical composition with cyclosporin as the active ingredient that does not contain dangerous neurotoxic emulsifiers and irritants found in vascular and oral formulations.
- DMSO dimethyl sulf oxide
- Dimethyl sulfoxide is an industrial solvent derived from wood. It is biocompatible, but approved in only one condition for human use, that of interstitial cystitis, a completely unrelated bladder condition. DMSO may by itself be useful for other conditions such as scleroderma, arthritis, mental illness, and brain trauma, but is not accepted into general medical use for these conditions.
- Cyclosporins are highly lipid soluble.
- mixtures for oral and intravenous administration usually involving a carrier solution of lipid in water emulsion, micro-emulsion or nano-emulsion or particles.
- this lipid in water emulsion is designed to allow administration in fluid phase mixed with salt-water solution to allow easy flow without precipitation of cyclosporin in the administering tubing or the blood. This has been acceptable in the past for simple intravenous (or oral) administration at the relatively low doses needed to treat immune rejection in transplantation or autoimmmune disease.
- cyclosporin is neuroprotective when it comes into contact with neurons. Since the drugs are also systemically immunosuppressive, it would be desirable to administer them selectively into the brain or the cerebrospinal fluid around the brain. Nonsystemic local CSF administration of cyclosporin would reduce systemic immune suppression, and increase brain and spine neuron exposure compared to systemic administration, both very desirable goals in patients in need of neuroprotection but not in need of immunosuppression. Especially patients that need long term treatment neuroprotection (such as those with amyotrophic lateral sclerosis, Parkinson's disease and Alzheimer's disease), it is desirable to avoid the complication, or undesirable side effect of lifelong systemic immunosuppression.
- Lipids emulsifiers are used in Sandirnmune (Novartis' formulation for cyclosporin) such as a modified castor oil derivative (Labrafil and cremophore). These castor oil derivatives have been themselves found to be directly neurotoxic, and likely to be the cause of the reported cases of neurologic problems of encephalopathy, and seizures in transplant patients.
- lipids injected into the cerebrospinal fluid have been reported to cause severe complications of archnoiditis or inflammation around the spinal cord-such as the discontinued oil based Pantopaque intrathecal X-ray contrast used in spinal myelograms. Injecting lipids, even in micro or nano-emulsions into the cerebrospinal spaces would likely cause layering of the lipid, since the long column of fluid in the spine contains slow moving CSF, which is a very different milieu than the rapidly flowing and mixing turbulent arterial and venous blood. The layering of lipid and drug in the cerebrospinal fluid column would result in undesirable cyclosporin over or underdosage, depending on location.
- ethanol is a commonly used solvent for cyclosporin used in Sandimmune. and SangCya (Sangstat's cyclosporin formulation).
- Ethanol is a known neurotoxin, and is used for neurolysis or destruction of nerve roots by injection into the brain or cerebrospinal fluid spaces.
- DMSO dimethylsulf oxide
- DMSO easily crosses tissues barriers in its role as a solvent and carries in with it drugs dissolved in it. This is an advantage because it opens the blood-brain barrier and CSF-brain barrier to facilitate cyclosporin penetration into the brain.
- the two main methods for infusing the formulation will be via the cerebral ventricles and the thecal sac.
- a catheter placed through a scalp incision, a skull twist drill hole and the brain, will access the cerebral ventricles. If a short-term infusion of several days is desired the catheter would be remain externalized and then removed. If a long term infusion over months or years were desired, the skin would be closed over the catheter and an attached refillable reservoir or drug pump.
- Thecal sac infusion is typically by lumbar puncture in the lumbar spine (or less often at the top of the spine at the base of the skull).
- the spinal puncture needle is placed through the skin of the back and pierces the dura (thecal sac) which contains the CSF in which the spinal cord is floating.
- formulary drug can be infused into the CSF in one session via the needle, or over a week through a soft catheter.
- the soft catheter is connected under the skin to a refillable programmable pump that is usually implanted under he abdominal skin.
- this formulation is also superior for intravenous or intra-arterial administration.
- This formulation is also superior for intravenous or intra-arterial administration.
- the absence of systemic neurotoxic castor oil derivatives will reduce the well-known neurological complications.
- the tissue penetrating capabilities of DMSO will facilitate penetration of the blood-brain barrier by cyclosporin to come into contact with neurons to make it work better.
- the formulary drug can be administration by the routes including oral, sublingual, buccal, nasal, inhalation, parenteral (including intraperitoneal, intraorgan, subcutaneous, intradermal, intramuscular, intra-articular, venous (central, hepatic or peripheral), lymphatic, cardiac, arterial, including selective or superselective cerebral arterial approach, retrograde perfusion through cerebral venous system, via catheter into the brain parenchyma or ventricles), direct exposure or under pressure onto or through the brain or spinal tissue, or any of the cerebrospinal fluid ventricles, injections into the subarachnoid, brain cisternal, subdural or epidural spaces, via brain cisterns or lumbar puncture, intra and peri-ocular instillation including application by injection around the eye, within the eyeball, its structures and layers, as well as via enteral, bowel, rectal, vaginal, urethral or bladder cisternal.
- parenteral including intraperitoneal, intraorgan, subcutaneous,
- the formulary drug containing cyclosporin dissolved in DMSO, for administration into the brain and related structures, spinal cord and related structures, ventricular system and cerebrospinal fluid spaces can be manufactured and distributed containing, aqueous and non-aqueous injection solutions, other pharmaceutically active compounds, additives including anti-oxidants, bacteriostats and solutes and sugars such as mannitol to make the formulary drug isotonic, hypotonic or hypertonic with the cerebrospinal fluid; and also aqueous and non-aqueous sterile suspensions .
- the formulary drug can be manufactured and distributed in unit-dose or multi-dose containers, such as sealed glass or plastic ampoules, vials, bottles and bags as a liquid, and in a dry state requiring the addition of DMSO.
- the formulary drug for parenteral administration can be manufactured from cyclosporin, DMSO, aqueous sterile injection solutions, other pharmaceutically active compounds, additives including anti-oxidants, bacteriostats and solutes and sugars such as mannitol to make the formulary drug isotonic, hypotonic or hypertonic with the fluids of the recipient.
- the formulary drug can be manufactured and distributed in unit-dose or multi-dose containers, such as sealed glass or plastic ampoules, vials, bottles and bags as a liquid, and in a dry state requiring the addition of DMSO.
- the formulations are used in patients who require neuroprotection from neurological diseases of acute to chronic nature including stroke, brain hemorrhage, brain and spine trauma, ionizing radiation, neurotoxicity to vestibulocochlear structures, retinal detachment and neurodegeneration including amyotrophic lateral sclerosis, Parkinson's and Alzheimer's.
- the formulations are used in patients who require both neuroprotection from neurological disease and that their neuro-axis be immunocompromised, such as in neural transplantation, neural xenotransplantation, multiple sclerosis, HIN neuropathy and Guillain-Barre syndrome.
- the formulations are used in patients who require that they be immunocompromised, such as in transplantation and autoimmune disease.
- the formulations are used for topical application for patients who require immunocompromise of the skin for diseases such as psoriasis.
- the formulary drug generally contains from 0.1 to 90% of the treatment medication by weight of the total composition. Cerebrospinal doses between 5 mg and 5 gram per day are possible, with about 50-150 mg/day for chronic administration, and 100-1000 mg/day for acute administration being preferable. Amounts of from 0.0001 mg to 200 mg/kg, or preferably 0.001 to 50 mg/kg, of body weight per day for parenteral administration and 0.001 to 150 mg/kg orally, can be given. Nevertheless, it could be necessary to alter those dosage rates, depending on the condition, weight, and individual reaction of the subject to the treatment, and the mode in which the administration is carried out, and the stage of the disease process or interval of administration. It may thus be sometimes adequate to use less than the before stated minimum dose, while in other instances the upper limit must be surpassed to obtain therapeutic results. Examples:
- the formulary drug is made by dissolving 5 grams of cyclosporin into 20 grams dimethyl sulfoxide at room temperature. The solution thus obtained is made up to 25 ml with water. The solution is homogenized with stirring and filtered. The liquid is sterilized by radiation and then placed in a sealed container such as glass under inert gas atmosphere in doses of 1 , 5 or 25 ml.
- Sterile injectable concentrate formulary drug is administered, with or without dilution with for example isotonic saline, by infusion or by injection into cerebrospinal fluid spaces, brain, spine, vein or artery.
- a person in need of acute brain or spinal neuroprotection from trauma or stroke has the composition of example 1 injected into the cerebrospinal fluid of the ventricle of the brain through a burrhole in the skull, or into the cerebrospinal fluid of thecal sac via a lumbar puncture needle, or injected intravascularly.
- a person in need of chronic brain or spinal neuroprotection from neurodegenerative disease such as Parkinson's, Alzheimer's or amyotrophic lateral sclerosis has the composition of example 1 injected periodically by a reservoir or pump into the cerebrospinal fluid of a brain ventricle through a burrhole in the skull, or into the cerebrospinal fluid of the thecal sac via a lumbar catheter connected to a reservoir and pump.
- Example 4
- a person in need of neural immunosuppression for neural transplantation, neural xenotransplantation, or diseases with autoimmune components like multiple sclerosis, Guillain-Barr ⁇ , has the composition of example 1 injected periodically by a reservoir or pump into the cerebrospinal fluid of a ventricle of the brain through a burrhole in the skull, or into the cerebrospinal fluid of the spinal thecal sac via a lumbar catheter connected to a reservoir and pump.
- a person in need of systemic immunosuppression has intravenous injections or oral consumption of the compositions of examples 1.
- the present invention provides improved compositions for the administration of cyclosporin. Additionally the present invention provides a completely new composition suitable for administration directly into the new target of delivery, the cerebrospinal fluid to directly treat diseases of the brain, which previously described compositions are not suitable for, because of the neurotoxicity of their solvents.
- Rats receiving intraventricular cerebrospinal infusions showed no neurotoxicity, seizures or untoward effects.
- rats receiving injections intravenously showed no ill effects.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU28825/99A AU2882599A (en) | 1999-02-26 | 1999-02-26 | Cerebrospinal and vascular pharmaceutical composition and process for preparing the same |
ES99909670T ES2332390T3 (en) | 1999-02-26 | 1999-02-26 | PHARMACEUTICAL COMPOSITION, BRAIN AND VASCULAR AND PROCESS TO PREPARE IT. |
AT99909670T ATE441425T1 (en) | 1999-02-26 | 1999-02-26 | CEREBROSPINAL AND VASCULAR PHARMACEUTICAL PREPARATION AND METHOD FOR THE PRODUCTION THEREOF |
DK99909670T DK1091750T3 (en) | 1999-02-26 | 1999-02-26 | Cerebrospinal and vascular pharmaceutical composition and process for their preparation |
DE69941359T DE69941359D1 (en) | 1999-02-26 | 1999-02-26 | CEREBROSPINAL AND VASCULAR EFFECTIVE PHARMACEUTICAL PREPARATION AND METHOD FOR THE PRODUCTION THEREOF |
CA002330329A CA2330329C (en) | 1999-02-26 | 1999-02-26 | Cerebrospinal and vascular pharmaceutical composition and process for preparing the same |
PT99909670T PT1091750E (en) | 1999-02-26 | 1999-02-26 | Cerebrospinal and vascular pharmaceutical composition and process for preparing the same |
NZ508376A NZ508376A (en) | 1999-02-26 | 1999-02-26 | Cerebrospinal and vascular pharmaceutical composition and process for preparing the same |
PCT/US1999/004359 WO2000050058A1 (en) | 1999-02-26 | 1999-02-26 | Cerebrospinal and vascular pharmaceutical composition and process for preparing the same |
EP99909670A EP1091750B1 (en) | 1999-02-26 | 1999-02-26 | Cerebrospinal and vascular pharmaceutical composition and process for preparing the same |
US09/674,092 US7446093B1 (en) | 1999-02-26 | 2000-02-26 | Cerebrospinal and vascular pharmaceutical composition and process for preparing the same |
CY20091101256T CY1109563T1 (en) | 1999-02-26 | 2009-12-01 | PHARMACEUTICAL COMPOSITION FOR BREAST AND VASCULAR APPLICATION AND METHOD FOR PREPARING IT |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1999/004359 WO2000050058A1 (en) | 1999-02-26 | 1999-02-26 | Cerebrospinal and vascular pharmaceutical composition and process for preparing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000050058A1 true WO2000050058A1 (en) | 2000-08-31 |
Family
ID=22272265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/004359 WO2000050058A1 (en) | 1999-02-26 | 1999-02-26 | Cerebrospinal and vascular pharmaceutical composition and process for preparing the same |
Country Status (11)
Country | Link |
---|---|
US (1) | US7446093B1 (en) |
EP (1) | EP1091750B1 (en) |
AT (1) | ATE441425T1 (en) |
AU (1) | AU2882599A (en) |
CA (1) | CA2330329C (en) |
CY (1) | CY1109563T1 (en) |
DE (1) | DE69941359D1 (en) |
DK (1) | DK1091750T3 (en) |
ES (1) | ES2332390T3 (en) |
PT (1) | PT1091750E (en) |
WO (1) | WO2000050058A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002078670A1 (en) * | 2001-03-02 | 2002-10-10 | Neuron Therapeutics, Inc. | Neuroprotectants formulations and methods |
US20110124739A1 (en) * | 2003-12-19 | 2011-05-26 | Volker Brinkmann | Use of Sphingosine-1-phosphate (S1P) Receptor Agonists for the Treatment of Brain Degenerative Diseases |
US10123969B2 (en) | 2015-10-15 | 2018-11-13 | Wisconsin Alumni Research Foundation | Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811410A (en) * | 1989-09-21 | 1998-09-22 | Hyal Pharmaceutical Corporation | Method of administering of a hyaluronic acid and an NSAID to decrease side effects of the NSAID |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4649047A (en) * | 1985-03-19 | 1987-03-10 | University Of Georgia Research Foundation, Inc. | Ophthalmic treatment by topical administration of cyclosporin |
CH679119A5 (en) * | 1988-05-13 | 1991-12-31 | Sandoz Ag | |
US5221607A (en) * | 1989-09-18 | 1993-06-22 | Scios Nova Inc. | Assays and reagents for amyloid deposition |
US5252463A (en) * | 1990-06-22 | 1993-10-12 | The Du Pont Merck Pharmaceutical Company | Clipsin, a chymotrypsin-like protease and method of using same |
-
1999
- 1999-02-26 EP EP99909670A patent/EP1091750B1/en not_active Expired - Lifetime
- 1999-02-26 ES ES99909670T patent/ES2332390T3/en not_active Expired - Lifetime
- 1999-02-26 DE DE69941359T patent/DE69941359D1/en not_active Expired - Lifetime
- 1999-02-26 DK DK99909670T patent/DK1091750T3/en active
- 1999-02-26 WO PCT/US1999/004359 patent/WO2000050058A1/en active Application Filing
- 1999-02-26 CA CA002330329A patent/CA2330329C/en not_active Expired - Fee Related
- 1999-02-26 PT PT99909670T patent/PT1091750E/en unknown
- 1999-02-26 AT AT99909670T patent/ATE441425T1/en active
- 1999-02-26 AU AU28825/99A patent/AU2882599A/en not_active Abandoned
-
2000
- 2000-02-26 US US09/674,092 patent/US7446093B1/en not_active Expired - Fee Related
-
2009
- 2009-12-01 CY CY20091101256T patent/CY1109563T1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811410A (en) * | 1989-09-21 | 1998-09-22 | Hyal Pharmaceutical Corporation | Method of administering of a hyaluronic acid and an NSAID to decrease side effects of the NSAID |
US5827834A (en) * | 1989-09-21 | 1998-10-27 | Hyal Pharmaceutical Corporation | Method of using hyaluronic acid or its pharmaceutically acceptable salts for the treatment of disease |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002078670A1 (en) * | 2001-03-02 | 2002-10-10 | Neuron Therapeutics, Inc. | Neuroprotectants formulations and methods |
EP1370240A1 (en) * | 2001-03-02 | 2003-12-17 | Neuron Therapeutics, Inc. | Neuroprotectants formulations and methods |
EP1370240A4 (en) * | 2001-03-02 | 2004-09-22 | Neuron Therapeutics Inc | Neuroprotectants formulations and methods |
US20110124739A1 (en) * | 2003-12-19 | 2011-05-26 | Volker Brinkmann | Use of Sphingosine-1-phosphate (S1P) Receptor Agonists for the Treatment of Brain Degenerative Diseases |
US8519006B2 (en) * | 2003-12-19 | 2013-08-27 | Novartis Ag | Use of sphingosine-1 phosphate (S1P) receptor agonists for the treatment of brain degenerative diseases |
US10123969B2 (en) | 2015-10-15 | 2018-11-13 | Wisconsin Alumni Research Foundation | Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid |
Also Published As
Publication number | Publication date |
---|---|
DK1091750T3 (en) | 2009-12-21 |
AU2882599A (en) | 2000-09-14 |
DE69941359D1 (en) | 2009-10-15 |
US7446093B1 (en) | 2008-11-04 |
ATE441425T1 (en) | 2009-09-15 |
CA2330329A1 (en) | 2000-08-31 |
PT1091750E (en) | 2009-11-10 |
EP1091750A4 (en) | 2005-04-13 |
EP1091750A1 (en) | 2001-04-18 |
CY1109563T1 (en) | 2014-08-13 |
ES2332390T3 (en) | 2010-02-03 |
EP1091750B1 (en) | 2009-09-02 |
CA2330329C (en) | 2009-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP734A (en) | Method of treating a human with nervous insult with cyclosporin. | |
BG65417B1 (en) | Application of eritropoetin or eritropoetin derivatives for the treatment of cerebral ischaemia | |
JP2534998B2 (en) | Pharmaceutical composition containing peptides of the cholecystokinin-cererulein group for treating symptoms of respiratory tract, respiratory dysfunction and cardiovascular dysfunction | |
CN112641771B (en) | Composition for treating autodigestion | |
KR101801430B1 (en) | Cyclosporine emulsion | |
AU2019215801B2 (en) | Parenteral formulations and uses thereof | |
US7446093B1 (en) | Cerebrospinal and vascular pharmaceutical composition and process for preparing the same | |
EP1669078A1 (en) | Cerebrovascular regeneration/reconstruction promoters and nerve tissue secondary degeneration inhibitors comprising ginsenoside RB 1 | |
CN1216469A (en) | Peripheral circulation improvers for ophthalmic tissues containing dihydropyridines | |
CN106361700A (en) | Nalmefene hydrochloride nasal medicine administration preparation | |
US5380710A (en) | Pharmaceutical compositions containing ACTH (1-24) for the therapy of shock conditions and respiratory and cardiocirculatory insufficiences | |
WO2017211273A1 (en) | Dsg2-derived peptides | |
HU207455B (en) | Method for producing pharmaceutical preparations suitable for treating postischemical heart-troubles containing captoprile and in given case thrombolitic agent | |
JP2606835B2 (en) | Pharmaceutical composition and pharmaceutical kit containing ACTH fragment for treating shock symptoms, respiratory dysfunction and cardiovascular dysfunction | |
CN114129516A (en) | Isoelemicin compound emulsion and preparation method and application thereof | |
WO2000016794A1 (en) | Neuroimmunophilins for selective neuronal radioprotection | |
WO2001097812A1 (en) | Tetracyclic compounds-containing pharmaceutical preparations | |
MXPA01003029A (en) | Neuroimmunophilins for selective neuronal radioprotection | |
CN101366701A (en) | N, N-dimethyl collagen sugar-2, 6-diisopropyl benzene ester salt injection | |
NZ510739A (en) | Neuroimmunophilins for selective neuronal radioprotection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2330329 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 508376 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999909670 Country of ref document: EP Ref document number: 28825/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09674092 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999909670 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |